Sunday, June 8, 2025
6/8/2025
GAG AND CYCLOPHILIN IN HIV-1 REPLICATION - DESCRIPTION (provided by applicant): Efforts to discover new anti-HIV-1 therapies and to elicit effective anti-HIV-1 immunity have increasingly focused on human factors that regulate HIV-1 replication and pathogenesis. Cyclophilin A, a peptidyl-prolyl isomerase that regulates protein-folding and is itself a receptor for the immunosuppressive drug cyclosporine, binds HIV-1 Gag via the CA domain. The interaction stimulates HIV-1 reverse transcription in human cells but inhibits it in owl monkey (OMK) or macaque cells. These phenotypes appear to result from effects of cyclophilin A on HIV-1 CA accessibility to species-specific Lvl/Refl host restriction factors. Also, via a novel conformational switch, cyclophilin A inhibits the Itk tyrosine kinase, suggesting that Gag binding to cyclophilin A might contribute to HIV-1 pathogenesis by disrupting CD4 v T cell effector function. These and other observations made since the discovery of the Gag/cyclophilin A interaction in 1993 serve as the basis for current specific aims. Aim 1. Several complementary approaches will be used to clone OMK Lvl and human Refl, including a functional screen of a cDNA library from owl monkey cells, a modified two-hybrid screen using a CA-fusion bait that saturates OMK restriction, and subtraction libraries from cell line subclones selected for loss of restriction. Aim 2. As203, m-Cl-CCP, and PKl1195 all disrupt mitochondrial membrane potential and decrease Refl restriction. Select primate species will be challenged to determine if the drugs also inhibit Lvl. Preliminary data suggest that cyclophilin A protects HIV-1 from Refl; to test this hypothesis the effect of the drugs on HIV-1 infectivity will be examined in contexts where cyclophilin A or Refl are disrupted. Detailed biochemical and cell biological effects of the drugs will be characterized and contrasted with those of cyclosporine. Aim 3. Under pressure from cyclosporine, HIV-1 acquires mutations in sequences encoding a type II turn in CA that are sufficient to confer cyclosporine-resistance. In certain human cell lines, these mutants replicate poorly and are cyclosporine-dependent. Evidence that this is due to a new restriction activity present in certain individuals will be sought. Group O viruses have alterations in the same gag sequences, are cyclosporine-resistant, and will be examined for sensitivity to the same activity. Aim 4. It will be determined if HIV-1 Gag disrupts the cyclophilin A-Itk interaction and causes elevated Th2 cytokine and IL-2 expression from effector/memory CD4* T cells as is seen in cyclophilin A knockout mice. These immunologic abnormalities would be expected to contribute to HIV-1 replication and pathogenesis.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).